Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Altimmune	Verona Pharma	Akebia Therapeutics	Geron	Kala Pharmaceuticals
Symbol	NASDAQ:ALT	NASDAQ:VRNA	NASDAQ:AKBA	NASDAQ:GERN	NASDAQ:KALA
Price Information
Current Price	$13.27	$6.22	$3.12	$1.33	$5.43
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.8	1.7	1.8	1.4	1.7
Analysis Score	3.5	3.5	3.3	3.5	3.4
Community Score	3.3	3.5	2.7	2.7	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.8	1.7	0.8	1.7
Earnings & Valuation Score	0.6	0.6	1.3	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$31.75	$19.33	$7.83	$4.20	$21.33
% Upside from Price Target	139.26% upside	210.83% upside	151.07% upside	215.79% upside	292.88% upside
Trade Information
Market Cap	$492.98 million	$360.36 million	$498.91 million	$423.65 million	$350.68 million
Beta	1.51	0.4	2.11	1.5	0.43
Average Volume	1,459,344	112,035	5,681,742	3,335,652	2,336,044
Sales & Book Value
Annual Revenue	$5.80 million	N/A	$335 million	$460,000.00	$6.07 million
Price / Sales	85.00	N/A	1.49	920.97	57.77
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$2.97 per share	$3.28 per share	$3.32 per share	$0.68 per share	$0.86 per share
Price / Book	4.47	N/A	0.94	1.96	6.31
Profitability
Net Income	$-20,520,000.00	$-40,780,000.00	$-279,660,000.00	$-68,550,000.00	$-94,350,000.00
EPS	($0.98)	($3.10)	($1.63)	($0.36)	($2.76)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	23.28	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-659.33%	N/A	-126.86%	-21,631.02%	-1,794.36%
Return on Equity (ROE)	-46.39%	-115.93%	-68.51%	-43.76%	-93.73%
Return on Assets (ROA)	-38.32%	-73.68%	-34.01%	-37.24%	-43.09%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.04%	0.24%	0.10%	0.68%
Current Ratio	34.66%	2.99%	2.15%	9.60%	9.11%
Quick Ratio	34.66%	2.99%	1.67%	9.60%	8.73%
Ownership Information
Institutional Ownership Percentage	66.22%	54.51%	68.98%	55.51%	67.63%
Insider Ownership Percentage	2.70%	N/A	2.55%	7.70%	34.15%
Miscellaneous
Employees	43	25	379	53	188
Shares Outstanding	37.15 million	57.94 million	159.91 million	318.53 million	64.58 million
Next Earnings Date	5/12/2021 (Estimated)	8/13/2021 (Estimated)	5/10/2021 (Confirmed)	5/10/2021 (Confirmed)	8/5/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Given Consensus Recommendation of "Buy" by Analysts americanbankingnews.com - May 9 at 1:20 AM
	Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2021 Results - Earnings Call Transcript seekingalpha.com - May 7 at 4:40 AM
	Zacks: Analysts Anticipate Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Will Announce Quarterly Sales of $5.69 Million americanbankingnews.com - May 7 at 4:38 AM
	HC Wainwright Reaffirms Buy Rating for Kala Pharmaceuticals (NASDAQ:KALA) americanbankingnews.com - May 6 at 5:40 PM
	Kala PharmaceuticalsInc. (NASDAQ:KALA) Analysis: Is It The One You’re Looking For? stocksregister.com - May 6 at 1:29 PM
	Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference businesswire.com - May 6 at 1:29 PM
	Kala Pharmaceuticals rises before hours on mixed bag Q1 drugdeliverybusiness.com - May 5 at 12:26 PM
	Kala Pharma: Q1 Earnings Snapshot sfgate.com - May 5 at 7:26 AM
	Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update finance.yahoo.com - May 5 at 7:26 AM
	-$0.51 Earnings Per Share Expected for Kala Pharmaceuticals, Inc. (NASDAQ:KALA) This Quarter americanbankingnews.com - May 5 at 6:38 AM
	Small Cap Stock Kala Pharmaceuticals Inc. (KALA) is a Buy – Analysts marketingsentinel.com - May 4 at 3:40 PM
	Kala Pharmaceuticals Earnings Preview benzinga.com - May 4 at 3:40 PM
	Jefferies lifts Kala Pharmaceuticals Inc. [KALA] price estimate. Who else is bullish? dbtnews.com - May 4 at 10:39 AM
	Short Interest in Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Decreases By 14.8% americanbankingnews.com - May 4 at 3:22 AM
	Kala Pharmaceuticals, Inc. (NASDAQ:KALA): How Much Is It Worth And What Should Investors Do? marketingsentinel.com - April 30 at 2:49 PM
	Kala Pharmaceuticals (KALA) Set to Announce Earnings on Wednesday americanbankingnews.com - April 29 at 8:16 AM
	Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call finance.yahoo.com - April 28 at 12:17 PM
	Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Stock Forecast 2021: $49 Per Share With Bullish Signs marketingsentinel.com - April 27 at 11:11 AM
	Q1 2021 EPS Estimates for Kala Pharmaceuticals, Inc. Reduced by Analyst (NASDAQ:KALA) americanbankingnews.com - April 26 at 1:24 AM
	What Kind Of Shareholders Hold The Majority In Kala Pharmaceuticals, Inc.'s (NASDAQ:KALA) Shares? finance.yahoo.com - April 23 at 9:57 AM
	Kala Pharmaceuticals (NASDAQ:KALA) Share Prices Have Dropped 52% In The Last Three Years nasdaq.com - April 22 at 6:39 PM
	Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Stock: Looks Like An Option To Consider stocksregister.com - April 22 at 8:39 AM
	Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Stock Forecast for 2021: Bullish Signs Point to $49 per Share marketingsentinel.com - April 20 at 1:48 PM
	$4.04 Million in Sales Expected for Kala Pharmaceuticals, Inc. (NASDAQ:KALA) This Quarter americanbankingnews.com - April 20 at 5:56 AM
	Zacks: Analysts Expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Will Announce Quarterly Sales of $4.04 Million americanbankingnews.com - April 20 at 5:56 AM

Date	Company	Brokerage	Action
2/18/2021	Altimmune	B. Riley	Boost Price Target
2/10/2021	Altimmune	Guggenheim	Initiated Coverage
12/14/2020	Altimmune	Jefferies Financial Group	Initiated Coverage
11/24/2020	Altimmune	Evercore ISI	Reiterated Rating
7/30/2020	Altimmune	Piper Sandler	Initiated Coverage
7/28/2020	Altimmune	JMP Securities	Initiated Coverage
2/24/2020	Altimmune	Roth Capital	Initiated Coverage
5/29/2018	Altimmune	Dawson James	Reiterated Rating
5/3/2021	Verona Pharma	Canaccord Genuity	Lower Price Target
11/30/2020	Verona Pharma	Wedbush	Reiterated Rating
1/14/2020	Verona Pharma	SunTrust Banks	Boost Price Target
4/17/2019	Verona Pharma	BTIG Research	Initiated Coverage
3/15/2021	Akebia Therapeutics	HC Wainwright	Lower Price Target
3/15/2021	Akebia Therapeutics	Cantor Fitzgerald	Initiated Coverage
1/29/2021	Akebia Therapeutics	JPMorgan Chase & Co.	Downgrade
9/4/2020	Akebia Therapeutics	Morgan Stanley	Lower Price Target
9/4/2020	Akebia Therapeutics	Mizuho	Lower Price Target
8/11/2020	Akebia Therapeutics	Needham & Company LLC	Initiated Coverage
5/6/2020	Akebia Therapeutics	Royal Bank of Canada	Boost Price Target
8/3/2020	Geron	Stifel Nicolaus	Initiated Coverage
9/27/2018	Geron	S&P Equity Research	Lower Price Target
7/5/2018	Geron	(FBRC)	Initiated Coverage
11/30/2020	Kala Pharmaceuticals	Northland Securities	Reiterated Rating
5/29/2020	Kala Pharmaceuticals	Oppenheimer	Initiated Coverage

(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources